All Comments by Benjamin Wolozin

  1. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
  2. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.
  3. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.
  4. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function.
  5. Chaperone-like activity of synucleins.
  6. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.
  7. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
  8. Another Not-Quite-Parkinson's Model
  9. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).
  10. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells.
  11. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia.
  12. Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes.
  13. A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases abeta 42 generation in human cells.
  14. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production.
  15. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.